uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
194 articles about uniQure
-
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
11/22/2022
uniQure N.V. (NASDAQ: QURE) announced that its partner, global biotechnology leader CSL (ASX: CSL), has received approval from the U.S. Food and Drug Administration (FDA) for HEMGENIX® (etranacogene dezaparvovec-drlb), a one-time gene therapy for the treatment of adults 18 years of age and older living with hemophilia B.
-
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
11/17/2022
uniQure N.V. today announced that it will host a Virtual Research & Development Event on Tuesday, November 29, 2022 from 8:30 a.m. to 10:30 a.m. EST.
-
A Data Safety Monitoring Board overseeing the Phase Ib/II trial assessing UniQure's gene therapy for Huntington's disease recommended that enrollment in the higher-dose cohort could resume.
-
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/2/2022
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the third quarter of 2022 and highlighted recent progress across its business.
-
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
8/8/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2022 and highlighted recent progress across its business.
-
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company's president of R&D, Dr. Ricardo Dolmetsch.
-
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
-
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
6/23/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 22, 2022
6/22/2022
uniQure N.V. announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment.
-
CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/22/2022
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that the Company granted equity awards to 22 employees as a material inducement to commencing their employment.
-
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority ReviewIf approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B
5/24/2022
uniQure N.V. (NASDAQ: QURE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) submitted by CSL Behring for etranacogene dezaparvovec, an investigational gene therapy for the treatment of adults with hemophilia B.
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2022
5/11/2022
uniQure N.V. announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment.
-
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/2/2022
uniQure N.V. announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.
-
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
5/2/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2022 and highlighted recent progress across its business.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
2/25/2022
uniQure N.V. today reported its financial results for 2021 and highlighted recent progress across its business.
-
Three genome editing companies, Intellia Therapeutics, Editas Medicine and uniQure, are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.
-
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
2/7/2022
uniQure N.V. today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
12/16/2021
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced initial observations on the first four patients enrolled in the lower-dose cohort of its ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.